News

Lybra Bio has been featured in the Boston Globe highlighting the transformative potential of microneedles for drug delivery across multiple fields.

Our founder, Núria Puigmal Dominguez, was selected as part of the MassBioDrive 2024 Fall cohort. Through this opportunity, we collaborated with biotech leaders and mentors to accelerate our work in creating better therapies for patients suffering from autoimmune skin diseases.

Lybra is one of six recipients of Ignite’s Golden Ticket. We’ve begun operations at LabCentral and are excited to continue developing our platforms for the treatment of autoimmune skin diseases.

During Alopecia Areata Awareness Month, Lybra’s Academic Co-founder Dr. Natalie Artzi presented our novel microneedle drug delivery patch at the World Medical Innovation Forum. In her presentation, she shared Lybra Bio’s innovative delivery and therapeutic outcomes, especially for alopecia areata patients.

The Massachusetts Medical Device Development Center (M2D2) selected Lybra as a finalist for its annual $200K Challenge. This competition spotlights innovative early-stage medical device, diagnostic, and biotech companies, offering up to $200,000 in in-kind support.

The Harvard Business School announced its 2023-2024 Blavatnik Fellows, which included Lybra Co-Founder Nuria Pugimal. This program selects five Harvard MBA and PhD alumni each year to support in advancing high-potential ventures across the life sciences, biotech, and other innovation-driven industries.